These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2257083)

  • 21. Editorial overview: safety/toxicity threshold concepts in drug discovery and development.
    Johnson DE; Smith DA; Park BK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):24-6. PubMed ID: 15679167
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety.
    Lu AY
    Drug Metab Dispos; 1998 Dec; 26(12):1217-22. PubMed ID: 9860931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of metabolism and disposition studies in the safety assessment of pharmaceuticals.
    Smith RL
    Xenobiotica; 1988 Jan; 18 Suppl 1():89-96. PubMed ID: 3278491
    [No Abstract]   [Full Text] [Related]  

  • 25. [The current requirements for the preclinical study of the safety of new drugs].
    Arzamastsev EV; Liubimov BI
    Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306
    [No Abstract]   [Full Text] [Related]  

  • 26. Application of pharmaceutical profiling assays for optimization of drug-like properties.
    Di L; Kerns EH
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug targeting via retrometabolic approaches.
    Bodor N; Buchwald P
    Pharmacol Ther; 1997; 76(1-3):1-27. PubMed ID: 9535166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biocatalysis: synthesis of chiral intermediates for drugs.
    Patel RN
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):741-64. PubMed ID: 17117684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing transient binding drugs: a new concept for drug discovery.
    Ohlson S
    Drug Discov Today; 2008 May; 13(9-10):433-9. PubMed ID: 18468561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cunninghamella--a microbial model for drug metabolism studies--a review.
    Asha S; Vidyavathi M
    Biotechnol Adv; 2009; 27(1):16-29. PubMed ID: 18775773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of knowledge on drug metabolism for the safe use of drugs in humans.
    Oesch F
    Drug Metab Rev; 2009; 41(3):298-300. PubMed ID: 19601716
    [No Abstract]   [Full Text] [Related]  

  • 35. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADMET-SMi's fourth annual meeting. 1-2 July 2009, London, UK.
    Gater D
    IDrugs; 2009 Sep; 12(9):547-9. PubMed ID: 19697271
    [No Abstract]   [Full Text] [Related]  

  • 37. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biochemistry of drug metabolism--an introduction: part 1. Principles and overview.
    Testa B; Krämer SD
    Chem Biodivers; 2006 Oct; 3(10):1053-101. PubMed ID: 17193224
    [No Abstract]   [Full Text] [Related]  

  • 39. Protein-site targeting. Diversification of the drug discovery process.
    Krantz A
    Nat Biotechnol; 1998 Dec; 16(13):1294. PubMed ID: 9853592
    [No Abstract]   [Full Text] [Related]  

  • 40. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.